RT Journal Article
SR Electronic
T1 Interaction of inherited genetic variants in the NLRP3 inflammasome/IL-6 pathway with acquired clonal hematopoiesis to modulate mortality risk in patients with HFrEF
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.03.23289436
DO 10.1101/2023.05.03.23289436
A1 Cremer, Sebastian
A1 Katsaouni, Nikoletta
A1 Abplanalp, Wesley Tyler
A1 Berkowitsch, Alexander
A1 Kirschbaum, Klara
A1 Rieger, Michael A.
A1 Rapp, Steffen
A1 Wild, Philipp S.
A1 Dimmeler, Stefanie
A1 Schulz, Marcel H.
A1 Zeiher, Andreas M.
YR 2023
UL http://medrxiv.org/content/early/2023/05/05/2023.05.03.23289436.abstract
AB Aims Clonal hematopoiesis (CH), defined as the presence of an expanded blood cell clone due to acquired somatic mutations in leukemia driver genes, was shown to be associated with increased mortality in patients with chronic ischemic heart failure with reduced ejection fraction (HFrEF). Mechanistically, circulating monocytes of mutation carriers display increased expression of proinflammatory genes involved in inflammasome and IL-6 signaling. Inherited genetic variants (SNP) in the IL-6 pathway are well known to affect inflammatory activation. Therefore, we investigated whether known SNPs in genes encoding for components of the inflammasome/IL-6 signaling pathway modulate fatal outcomes in HFrEF patients with CH.Methods and Results In a total of 446 patients with chronic HFrEF, peripheral blood or bone marrow mononuclear cells were analyzed for the CH driver mutations DNMT3A and TET2 as well as 48 preselected SNPs affecting genes in the NLRP3 inflammasome/IL-6 signaling pathway. The 103 patients carrying a CH driver mutation demonstrated significantly increased mortality compared to the 343 patients without CH mutations (25,24% vs 13.99% at five years; p=0.0064). We identified three commonly occurring variants known to disrupt IL-6 signaling (rs2228145, rs4129267 and rs4537545), which are in strong linkage disequilibrium and present in more than 50% of CH carriers. Harboring one of those SNPs abrogated the increased mortality risk in patients with HFrEF and CH (p≤0.05 for each SNP). On the contrary, three different SNPs (rs2250417, which is associated with increased IL-18 levels; rs4722172 and rs4845625, which are known to activate IL-6 signaling) were identified to mediate fatal outcomes in patients with HFrEF and CH; p<0.05 for each). None of the assessed SNPs influenced outcomes in patients without DNMT3A or TET2 mutations. Single Cell RNA-sequencing of circulating monocytes of patients with HFrEF revealed increased inflammatory signaling in DNMT3A mutation carriers harboring IL6/IL18 activating SNPs with genes upregulated in pathways such as “cellular response to stress”, “regulation of cell activation” and “cytokine signaling in the immune system”.Conclusion Among CH carriers with HFrEF, inherited variants in loci encoding for genes involved in inflammatory signaling interact with mortality risk. These data not only provide mechanistic insights into inflammatory mechanisms contributing to fatal outcome of HFrEF in CH carriers, but may also inform trials evaluating precision-targeted anti-inflammatory therapy in patients with DNMT3A and TET2 mutations and chronic HFrEF.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding from the Alfons und Gertrud Kassel-Stiftung as part of the center for data science and AI to NK, MHS and AMZ. This work was supported by the DZHK (German Centre for Cardiovascular Research), the German research Foundation (Exc 2026/1), the Dr. Robert Schwiete Foundation (to SD), the Willy Robert Pitzer Stiftung (to SC) and the Jose Carreras Leukaemie-Stiftung (grant DJCLS 11 R/2020 to M.A.R.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients provided written informed consent for one of the following registered clinical trials: TOPCARE-CHD (NCT00289822 or NCT00962364), Cellwave (NCT00326989), or REPEAT (NCT 01693042). Supplementary to the clinical trials, patients provided additional informed consent for genetic testing of bone marrow and/or blood samples. The ethics review board of the Goethe University in Frankfurt, Germany, approved the protocols. The study complies with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors